No human trial has set a standard NAD⁺ dose under the tongue; your specific product’s label, or your clinician, is the only guidance that applies.
Human trials have tested oral NAD⁺ precursors — nicotinamide riboside, nicotinamide mononucleotide, NADH — and not one of them tested a sublingual product or produced a number you can copy onto a dropper.
For that reason, getting the NAD sublingual dosage right means reading the bottle, not the studies. Here is what the human research does cover, why the figures quoted online don’t transfer, and what deserves your attention before you hold anything under your tongue.
What Human Studies Actually Cover
The clinical evidence covers oral NAD⁺ precursors, not a sublingual product, so no study-based sublingual dose exists to follow.
A 2024 systematic review pooled 10 randomized studies and 489 participants. Across the NAD-related compounds it examined, oral doses ran from 4 mg to 1,000 mg per day. The authors concluded that further research is needed before anyone can name a clinical benefit or a correct dose, and the 2024 systematic review never tested a product held under the tongue. The compounds it did cover were studied as oral doses, not as drops or tablets kept beneath the tongue.
A second review of 33 human intervention studies found that oral nicotinamide riboside and nicotinamide mononucleotide do raise NAD-related biomarkers, but clinically meaningful outcomes stayed mixed and unproven. A biomarker moving is not the same as a person feeling better.
Can You Copy A Dose From NR Or NMN Research?
No. Nicotinamide riboside, nicotinamide mononucleotide, and NADH are chemically distinct from NAD⁺, and their absorption, bioavailability, and evidence cannot be assumed to carry over to a sublingual dose.
The reviews also logged side effects. Reported events across the randomized trials included muscle pain, nervous-system symptoms, fatigue, sleep disturbance, and headache, none classified as serious. Nicotinamide mononucleotide studies more often reported mild-to-moderate digestive trouble such as diarrhea and abdominal pain, and the later meta-analysis added mouth ulcers and skin problems.
Two mistakes show up constantly: treating an oral NR or NMN study dose as a sublingual instruction, and reading a supplement label as proof of FDA approval. Neither survives a look at the evidence, which is what the table below makes plain.
| Compound Studied In Humans | Reported Study Doses | What It Says About Sublingual NAD⁺ |
|---|---|---|
| NAD-related oral compounds | 4–1,000 mg per day across 10 randomized trials | Establishes no sublingual dose |
| Nicotinamide riboside (NR) | Oral doses only | Raises NAD-related biomarkers; no sublingual protocol tested |
| Nicotinamide mononucleotide (NMN) | Oral doses only | Mild-to-moderate digestive effects reported; no sublingual dose |
| NADH | Studied orally in the same review | No sublingual regimen established |
| Sublingual NAD⁺ | No human dosing trials identified | Dose comes from the label, not the literature |
Sublingual NAD⁺ Dosage: What The Label Decides
No evidence-based rule says to take NAD⁺ under the tongue in the morning, on an empty stomach, before meals, or at bedtime. Those timings come from product copy, not from human data. Where a product is legally sold and carries a verified label, that label’s serving size and timing are the only instructions with any grounding behind them.
Holding a liquid under the tongue for a minute or two before swallowing is a habit, not documented manufacturer guidance — unless your specific product says otherwise on its own label.
If you’re comparing bottles rather than doses, our roundup of tested sublingual NAD products shows what the labels actually state.
Five things worth checking before anything goes under your tongue:
- Serving size and concentration on the label — measure with the dropper or scoop the product ships with, not a kitchen spoon.
- The expiration date and storage instructions; most liquids want a cool, dark spot.
- Clinician input first if you are pregnant or breastfeeding, under 18, have significant liver or kidney disease, active cancer, or take prescription medicines.
- A stop rule: new digestive upset, fatigue, sleep changes, or headaches mean a conversation with a doctor, not a bigger dose.
Common Questions
Does Holding NAD⁺ Under The Tongue Absorb Better Than Swallowing It?
No human trial has compared a sublingual NAD⁺ dose with a swallowed one, so the absorption advantage claimed on product pages is unproven. Placement under the tongue does change absorption for certain prescription drugs, but that has not been demonstrated for NAD⁺ supplements. Pay for the label you can verify, not for an absorption promise nobody has tested in people.
What Time Of Day Should Sublingual NAD⁺ Be Taken?
There is no established time. Suggestions to take it in the morning, on an empty stomach, or before bed are marketing habits, not findings from the human studies reviewed here. If your product’s label gives a timing instruction, follow that. If a clinician who knows your prescription list and health history gives you a schedule, follow that instead.
What Are The Downsides Of NAD⁺ Supplements?
Trials have reported muscle pain, nervous-system symptoms, fatigue, sleep disturbance, headaches, and mild-to-moderate digestive upset, with no serious events. Long-term safety is still poorly characterized. Nothing in the human evidence shows these products treat aging, cognitive decline, or metabolic disease, so anyone pregnant, breastfeeding, under 18, or managing liver or kidney problems should get clinician advice first.
Sources
- American Journal of Physiology — Endocrinology and Metabolism. 2024 systematic review of NAD-related interventions in humans. Supports the 10 randomized studies, 489 participants, the 4–1,000 mg per day oral range, and the reported adverse effects.
- Critical Reviews in Food Science and Nutrition. Review of 33 human intervention studies on NR and NMN. Supports the biomarker findings and the digestive, mouth ulcer, and skin effects noted.
- National Center for Biotechnology Information. Human evidence on NAD⁺ supplementation and health outcomes. Supports the conclusion that clinical effectiveness for aging and disease remains unproven.